Log In
BCIQ
Print this Print this
 

CD40LGVAX

  Manage Alerts
Collapse Summary General Information
Company Cellular Biomedicine Group Inc.
DescriptionVaccine consisting of irradiated allogeneic lung adenocarcinoma cells combined with a cell line transfected with human CD40L and GM-CSF
Molecular Target CD40 ; Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$29.3M

$2.5M

0


 Deals Details
Get a free BioCentury trial today